

Core HTA (WP4)

EUnetHTA / Medical Technology – HTA Expert Meeting
Brussels, Belgium. October 16, 2015

Tom Jefferson, EUnetHTA WP4
jefferson@agenas.it

Fecal Immunochemical Test (FIT) versus guaiac-based fecal occult blood test (FOBT) for colorectal cancer screening

<https://mekat.thl.fi/htacore/ProjectHome.aspx?id=206&crumb=2>

Core HTA 1

Was it HTA?

Use of Intravenous immunoglobulins for Alzheimer's disease including Mild Cognitive Impairment

<https://mekat.thl.fi/htacore/ViewDraft.aspx?p=267&id=19539>

Core HTA 2

Logistical difficulties

Arguments on the choice of topic

Arguments on the comparator

No effects of any kind observed

Inclusion of register data

No access to unpublished data

Core HTA 3

Structured telephone support (STS) for adult patients with chronic heart failure (as yet unpublished)

Core HTA 3

Wooliness of topic/PICO

Difficulties in managing huge heterogeneous group (16 member agencies)

Delays

Invaluable support of COCIR/EUCOMED

Core HTA 3

Wooliness of topic/PICO

Difficulties in managing huge heterogeneous group (16 member agencies)

Delays

Invaluable support of COCIR/EUCOMED

Discussion points

- Regulation based on conformity – not on evidence of effect
- «Device» denominator
- Device families/unclear taxonomy
- Mutual astroturfing
- Assessment methods unclear
- Important vs less important devices
- Industry/HTA relationship
- HTA agencies' competence

